Warrington and Halton<\/p><\/td> | 11,562<\/p><\/td> | 15,957<\/p><\/td><\/tr><\/tbody><\/table> <\/p> In addition to payments made for medical staff, the figures in the above table include the costs of temporary and agency workers engaged in other activities, such as employees contracted for provision of other administration and support services.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1542", "label" : {"_value" : "Biography information for Philip Dunne"}
}
, "answeringMemberConstituency" : {"_value" : "Ludlow"}
, "answeringMemberPrinted" : {"_value" : "Mr Philip Dunne"}
, "dateOfAnswer" : {"_value" : "2016-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-10-19T15:53:29.733Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-10-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hospitals: Agency Workers"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much (a) Royal Liverpool and Broadgreen University Hospital NHS Trust, (b) St Helens and Knowsley Hospital Services NHS Trust, (c) Aintree University Hospitals NHS Foundation Trust, (d) Wirral University Teaching Hospital NHS Foundation Trust, (e) Southport and Ormskirk NHS Trust and (f) Warrington and Halton Hospitals NHS Foundation Trust spent on agency medical staff in (i) 2014-15 and (ii) 2015-16.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/481", "label" : {"_value" : "Biography information for Sir George Howarth"}
}
, "tablingMemberConstituency" : {"_value" : "Knowsley"}
, "tablingMemberPrinted" : [{"_value" : "Mr George Howarth"}
], "uin" : "48122"}
, {"_about" : "http://data.parliament.uk/resources/599471", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/599471/answer", "answerText" : {"_value" : " Improving early diagnosis of cancer is a priority for this Government, and was clearly highlighted in the report Achieving World-Class Cancer Outcomes published last year by the Independent Cancer Taskforce. Earlier diagnosis makes it more likely that patients, including children with cancer, will receive effective treatments. We have committed to implementing all the recommendations of the Taskforce including that, by 2020, everyone referred with a suspicion of cancer will receive either a definitive diagnosis or the all-clear within four weeks (28 days).<\/p> NHS England has the funds necessary to improve cancer services over the next five years, including up to £300 million by 2020 to support earlier diagnosis of cancer and the £10 billion of real terms increase in National Health Service funding by 2020-21. The recommendations in the Taskforce report give direction as to where these funds should be targeted.<\/p> In order to continue to support general practitioners (GPs) to identify patients whose symptoms may indicate cancer and urgently refer them as appropriate, the National Institute for Health and Care Excellence (NICE) published an updated suspected cancer referral guideline in June 2015. The guideline \u2018Suspected cancer: recognition and referral\u2019 includes new recommendations for childhood cancers.<\/p> NICE also addressed generally, non-site specific symptoms of concern in children and young people, recommending that GPs should take into account the insight and knowledge of parents and carers when considering making a referral for suspected cancer. NICE noted that more lives could be saved each year in England if GPs followed the new guideline, which encourages GPs to think of cancer sooner and lower the referral threshold.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4080", "label" : {"_value" : "Biography information for David Mowat"}
}
, "answeringMemberConstituency" : {"_value" : "Warrington South"}
, "answeringMemberPrinted" : {"_value" : "David Mowat"}
, "dateOfAnswer" : {"_value" : "2016-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-10-19T14:41:21.11Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-10-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Children"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to improve early diagnosis of childhood cancers; and if he will make available additional funding to improve such early diagnosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "48110"}
, {"_about" : "http://data.parliament.uk/resources/599473", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/599473/answer", "answerText" : {"_value" : " NHS England has advised that the Chemotherapy Clinical Reference Group (CRG) discussed the use of bisphosphonates for the indication of preventing secondary breast cancer during a meeting held in September 2015. It was raised in the context of guidance being developed by the Breast Cancer Clinical Reference Group and whether, through the Chemotherapy CRG, NHS England could implement any policy to support the use of these drugs. It was confirmed that these drugs would need to be commissioned by clinical commissioning groups.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
}
, "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"}
, "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"}
, "dateOfAnswer" : {"_value" : "2016-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-10-19T15:04:06.43Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-10-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Breast Cancer: Chemotherapy"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what discussions the Chemotherapy Clinical Reference Group has had on the use of bisphosphonates for the indication of preventing secondary breast cancer since July 2015.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/312", "label" : {"_value" : "Biography information for Dame Caroline Spelman"}
}
, "tablingMemberConstituency" : {"_value" : "Meriden"}
, "tablingMemberPrinted" : [{"_value" : "Dame Caroline Spelman"}
], "uin" : "48107"}
, {"_about" : "http://data.parliament.uk/resources/599475", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/599475/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) is currently developing guidance on four drugs through the highly specialised technology (HST) evaluation programme which it expects to complete within the next year. NICE has capacity to develop guidance on three HST topics each year.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
}
, "answeringMemberConstituency" : {"_value" : "Oxford West and Abingdon"}
, "answeringMemberPrinted" : {"_value" : "Nicola Blackwood"}
, "dateOfAnswer" : {"_value" : "2016-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-10-19T15:08:06.257Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-10-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many NICE highly specialised technology evaluations are expected to take place over the next two years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/481", "label" : {"_value" : "Biography information for Sir George Howarth"}
}
, "tablingMemberConstituency" : {"_value" : "Knowsley"}
, "tablingMemberPrinted" : [{"_value" : "Mr George Howarth"}
], "uin" : "48117"}
, {"_about" : "http://data.parliament.uk/resources/599479", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/599479/answer", "answerText" : {"_value" : " As part of the revised arrangements for the Clinical Reference Groups (CRGs), which support specialised commissioning, NHS England has also announced the establishment of cross-CRG working parties, including some which will work with other health and care bodies to contribute to improving services, data and efficiency. These are not distinct CRGs, but a collaboration between existing groups.<\/p> Those working parties are:<\/p> - Research \u2013 building an interface with the National Institute for Health Research to advise how future research strategies align with commissioning and maximising opportunities;<\/p> - Data and Resource \u2013 working with NHS Digital and NHS Improvement to provide clinical advice to these organisations in their work to improve the information that guides commissioning;<\/p> - Guidance \u2013 working with the National Institute for Health and Care Excellence as a stakeholder in their guidance development and providing clinical advice as needed; and<\/p> - Value \u2013 to better understand, and therefore reduce, variations in services and, where appropriate, cease treatments/ways of working that are no longer of clinical or patient benefit.<\/p> These relate to the specialised commissioning CRGs and there is no link to the clinical expert groups.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4080", "label" : {"_value" : "Biography information for David Mowat"}
}
, "answeringMemberConstituency" : {"_value" : "Warrington South"}
, "answeringMemberPrinted" : {"_value" : "David Mowat"}
, "dateOfAnswer" : {"_value" : "2016-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-10-19T14:59:07.977Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-10-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Clinical Reference Groups"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 19 September 2016 to Question 46209, what the relationship will be between the clinical expert groups and the recently established cross-Clinical Reference Group working parties.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol West"}
, "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"}
], "uin" : "48106"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-questionFirstAnswered.=2016-02-17T14%3A11%3A37.907Z&AnswerDate=2016-10-13&AnsweringBody.=Department+of+Health&min-ddpModified.=2016-10-19T10%3A41%3A04.760Z&max-questionFirstAnswered.=2017-04-05T11%3A01%3A54.127Z", "page" : 0, "startIndex" : 1, "totalResults" : 43, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|